![Martin Scurr](https://profiles-cardiff.imgix.net/attachments/6822?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Trosolwyg
Rwy'n Gymrawd Ymchwil yn yr Is-adran Heintiau ac Imiwnedd, a ariennir gan gynllun Cymrodoriaeth Uwch Ymchwil Iechyd a Gofal Cymru. Rwyf hefyd yn Brif Swyddog Gwyddonol gydag ImmunoServ Ltd. Mae fy ymchwil yn canolbwyntio ar imiwnoleg celloedd T, gan ddatblygu profion newydd i fesur ymatebion celloedd T sy'n benodol i antigenau ar draws ystod o glefydau, gan gynnwys ffliw, sglerosis ymledol a chanser.
Cyhoeddiad
2024
- Hopkins, G. et al. 2024. Lower humoral and cellular immunity following asymptomatic SARS-CoV-2 infection compared to symptomatic infection in education (the ACE cohort). Journal of Clinical Immunology 44(6), article number: 147. (10.1007/s10875-024-01739-0)
2023
- Ambati, S. et al. 2023. Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T. International Journal of Hematology (10.1007/s12185-022-03518-2)
2022
- Scurr, M. J. et al. 2022. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature Communications 13, article number: 5422. (10.1038/s41467-022-32985-8)
- Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64, article number: 103937. (10.1016/j.msard.2022.103937)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165(2), pp. 250-259. (10.1111/imm.13433)
- Bradley, R. E. et al. 2022. Persistent COVID-19 infection in Wiskott-Aldrich syndrome cleared following therapeutic vaccination: a case report. Journal of Clinical Immunology 42, pp. 32-35. (10.1007/s10875-021-01158-5)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91(1), pp. 89-100. (10.1002/ana.26251)
2021
- Thomson, A. et al. 2021. Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. British Journal of Cancer 124, pp. 1552-1555. (10.1038/s41416-021-01283-3)
2020
- Lauder, S. N. et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8(2), article number: e000693. (10.1136/jitc-2020-000693)
- Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
2019
- Thomson, A. et al. 2019. The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology 19, article number: 98. (10.1186/s12876-019-1002-4)
- Besneux, M. et al. 2019. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy 68, pp. 247-256. (10.1007/s00262-018-2266-1)
2018
- Hughes, E., Scurr, M., Campbell, E., Jones, E., Godkin, A. and Gallimore, A. 2018. T‐cell modulation by cyclophosphamide for tumour therapy. Immunology 154(1), pp. 62-68. (10.1111/imm.12913)
2017
- Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
- Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
- Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35(7), pp. 154-154. (10.1200/JCO.2017.35.7_suppl.154)
2016
- Clement, M. et al. 2016. Cytomegalovirus-specific IL-10-producing CD4+ T cells are governed by type-I IFN-induced IL-27 and promote virus persistence. Plos Pathogens 12(12), article number: e1006050. (10.1371/journal.ppat.1006050)
2015
- Holland, C. J. et al. 2015. Enhanced detection of antigen-specific CD4+ T cells using altered peptide flanking residue peptide-MHC class II multimers. Journal of Immunology 195(12), pp. 5827-5836. (10.4049/jimmunol.1402787)
- Scurr, M. J. et al. 2015. Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. JNCI: Journal of the National Cancer Institute 107(4), article number: djv001. (10.1093/jnci/djv001)
2013
- Scurr, M. et al. 2013. Escalating regulation of 5T4-specific IFN- + CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunology Research 1(6), article number: 416. (10.1158/2326-6066.CIR-13-0035)
- Scurr, M. J. et al. 2013. Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunology n/a (10.1038/mi.2013.62)
- Davies, L. C. et al. 2013. Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation. Nature Communications 4, article number: 1886. (10.1038/ncomms2877)
- Scurr, M. J. 2013. Elucidating the impact of CD4+ T cells on tumour progression in patients with colorectal cancer. PhD Thesis, Cardiff University.
2012
- Scurr, M. J., Gallimore, A. M. and Godkin, A. J. 2012. T cell subsets and colorectal cancer: discerning the good from the bad. Cellular Immunology 279(1), pp. 21-24. (10.1016/j.cellimm.2012.08.004)
- Scurr, M. J., Gallimore, A. M. and Godkin, A. J. 2012. PMO-088 A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression. Gut 61(S2), article number: A109. (10.1136/gutjnl-2012-302514b.88)
- Betts, G. J. et al. 2012. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 61(8), pp. 1163-1171. (10.1136/gutjnl-2011-300970)
2011
- Clark, S. R. et al. 2011. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood 117(6), pp. 2033-2043. (10.1182/blood-2010-04-278887)
Articles
- Hopkins, G. et al. 2024. Lower humoral and cellular immunity following asymptomatic SARS-CoV-2 infection compared to symptomatic infection in education (the ACE cohort). Journal of Clinical Immunology 44(6), article number: 147. (10.1007/s10875-024-01739-0)
- Ambati, S. et al. 2023. Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T. International Journal of Hematology (10.1007/s12185-022-03518-2)
- Scurr, M. J. et al. 2022. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature Communications 13, article number: 5422. (10.1038/s41467-022-32985-8)
- Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64, article number: 103937. (10.1016/j.msard.2022.103937)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165(2), pp. 250-259. (10.1111/imm.13433)
- Bradley, R. E. et al. 2022. Persistent COVID-19 infection in Wiskott-Aldrich syndrome cleared following therapeutic vaccination: a case report. Journal of Clinical Immunology 42, pp. 32-35. (10.1007/s10875-021-01158-5)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91(1), pp. 89-100. (10.1002/ana.26251)
- Thomson, A. et al. 2021. Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. British Journal of Cancer 124, pp. 1552-1555. (10.1038/s41416-021-01283-3)
- Lauder, S. N. et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8(2), article number: e000693. (10.1136/jitc-2020-000693)
- Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
- Thomson, A. et al. 2019. The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology 19, article number: 98. (10.1186/s12876-019-1002-4)
- Besneux, M. et al. 2019. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy 68, pp. 247-256. (10.1007/s00262-018-2266-1)
- Hughes, E., Scurr, M., Campbell, E., Jones, E., Godkin, A. and Gallimore, A. 2018. T‐cell modulation by cyclophosphamide for tumour therapy. Immunology 154(1), pp. 62-68. (10.1111/imm.12913)
- Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
- Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
- Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35(7), pp. 154-154. (10.1200/JCO.2017.35.7_suppl.154)
- Clement, M. et al. 2016. Cytomegalovirus-specific IL-10-producing CD4+ T cells are governed by type-I IFN-induced IL-27 and promote virus persistence. Plos Pathogens 12(12), article number: e1006050. (10.1371/journal.ppat.1006050)
- Holland, C. J. et al. 2015. Enhanced detection of antigen-specific CD4+ T cells using altered peptide flanking residue peptide-MHC class II multimers. Journal of Immunology 195(12), pp. 5827-5836. (10.4049/jimmunol.1402787)
- Scurr, M. J. et al. 2015. Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. JNCI: Journal of the National Cancer Institute 107(4), article number: djv001. (10.1093/jnci/djv001)
- Scurr, M. et al. 2013. Escalating regulation of 5T4-specific IFN- + CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunology Research 1(6), article number: 416. (10.1158/2326-6066.CIR-13-0035)
- Scurr, M. J. et al. 2013. Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunology n/a (10.1038/mi.2013.62)
- Davies, L. C. et al. 2013. Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation. Nature Communications 4, article number: 1886. (10.1038/ncomms2877)
- Scurr, M. J., Gallimore, A. M. and Godkin, A. J. 2012. T cell subsets and colorectal cancer: discerning the good from the bad. Cellular Immunology 279(1), pp. 21-24. (10.1016/j.cellimm.2012.08.004)
- Scurr, M. J., Gallimore, A. M. and Godkin, A. J. 2012. PMO-088 A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression. Gut 61(S2), article number: A109. (10.1136/gutjnl-2012-302514b.88)
- Betts, G. J. et al. 2012. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 61(8), pp. 1163-1171. (10.1136/gutjnl-2011-300970)
- Clark, S. R. et al. 2011. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood 117(6), pp. 2033-2043. (10.1182/blood-2010-04-278887)
Thesis
- Scurr, M. J. 2013. Elucidating the impact of CD4+ T cells on tumour progression in patients with colorectal cancer. PhD Thesis, Cardiff University.
Ymchwil
Mae fy ymchwil yn ymchwilio i ffenoteip, swyddogaeth a mesur safonedig celloedd T canser, bacteria a firysau-benodol. Bydd fy mhrosiect Uwch Gymrodoriaeth HCRW yn creu ac yn asesu effeithiolrwydd cell T cyfunol a phrawf gwaed gwrthgyrff i fesur a nodi cydberthyn imiwnolegol a achosir gan frechlyn o amddiffyniad rhag haint ffliw.
Mae fy ngwaith blaenorol hefyd wedi datgelu effeithiau ataliol rhai poblogaethau o diwmor sy'n ymdreiddio celloedd T ar gelloedd T gwrth-ganser eraill, gan arwain at ddylunio a gweithredu treial clinigol cam I / II, TaCTiCC®, gan brofi cyfuniad imiwnotherapiwtig newydd mewn cleifion CRC datblygedig. Yn dilyn hyn, rydw i'n ymchwilio ar hyn o bryd a all cyclophosphamide dos isel atal ailwaelu mewn 500 o gleifion CRC ôl-lawfeddygol a recriwtiwyd i'r treial cam II, BICCC.
Yn ogystal â hyn, fi hefyd yw cyd-sylfaenydd a phrif swyddog gwyddonol ImmunoServ, cwmni biotechnoleg o Gaerdydd sy'n arbenigo yn y sector imiwnoleg, gyda'i biblinell Ymchwil a Datblygu ei hun ar gyfer datblygu ystod o brofion gwaed sy'n mesur ymatebion celloedd T i firysau, bacteria a chanser. Rwy'n brif ymchwilydd ar sawl prosiect i ddatblygu profion celloedd T ar gyfer diagnosteg a sgriniau imiwnedd ar raddfa poblogaeth ar draws ystod o glefydau.
Bywgraffiad
2024-presennol: Cymrawd Uwch HCRW, Prifysgol Caerdydd
2020-presennol: Prif Swyddog Gwyddonol, ImmunoServ
2013-2020: Ymchwil Ôl-ddoethurol, Prifysgol Caerdydd
2009-2013: PhD (Imiwnoleg Canser), Prifysgol Caerdydd
Anrhydeddau a dyfarniadau
2022: Gwobr Arloesi MediWales
Aelodaethau proffesiynol
- Cymdeithas Imiwnoleg Prydain
- MediWales
Pwyllgorau ac adolygu
- Asesydd ar gyfer Innovate UK
- Aelod o Grŵp Cynghori 'Diwydiant ac Arloesi' a ariennir gan Wellcome/CEPI
- adolygydd cymheiriaid ar gyfer sawl cyfnodolyn academaidd
Contact Details
ScurrMJ@caerdydd.ac.uk
+44 29206 87080
Canolfan Meddygol Caerdydd, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4UJ
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Llawr 3, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
+44 29206 87080
Canolfan Meddygol Caerdydd, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4UJ
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Llawr 3, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Themâu ymchwil
Arbenigeddau
- Imiwnoleg
